论文部分内容阅读
目的:探讨乌司他丁对合并凝血功能障碍危重症患者的临床效果。方法:将60例合并凝血功能障碍的危重患者随机分为对照组和观察组。对照组给予常规对症治疗;观察组在此基础上每次给予乌司他丁20万U静脉注射,每日1~3次,连续治疗1周。记录并比较两组患者入院时及治疗1周后血小板计数、凝血酶原时间、部分活化凝血酶原时间、D-D二聚体、APACHE评分和DIC评分。结果:治疗后血小板计数观察组明显高于治疗前和对照组治疗,凝血酶原时间、部分活化凝血酶原时间均明显短于治疗前和对照组治疗,血D-D二聚体含量明显低于治疗前和对照组治疗;治疗后观察组患者的APACHE评分和DIC评分明显低于治疗前和对照组,差异均有统计学意义(P<0.05)。结论:乌司他丁可以明显改善危重患者的凝血功能障碍,降低患者的病情严重程度。
Objective: To investigate the clinical effect of ulinastatin on critically ill patients with coagulopathy. Methods: Sixty critically ill patients with coagulation disorders were randomly divided into control group and observation group. The control group was given conventional symptomatic treatment; on the basis of this observation group, 200,000 U of ulinastatin was given intravenously once or three times daily for 1 week. The platelet count, prothrombin time, partial prothrombin time, D-D dimer, APACHE score and DIC score were recorded and compared at admission and after 1 week of treatment. Results: After treatment, the platelet count in the observation group was significantly higher than that before treatment and the control group, and the prothrombin time and partial prothrombin time were significantly shorter than those before treatment and in the control group. The DD level in blood was significantly lower than that in the treatment group Before and after treatment, APACHE score and DIC score in the observation group were significantly lower than those before treatment and in the control group (P <0.05). Conclusion: Ulinastatin can significantly improve coagulation disorders in critically ill patients and reduce the severity of the disease.